Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATHA 
Athira Pharma Inc (ATHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: ATHA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.88% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.16M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta 2.97 | 52 Weeks Range 2.20 - 6.68 | Updated Date 11/30/2025 |
52 Weeks Range 2.20 - 6.68 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.67 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.13 | Actual -1.68 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.21% | Return on Equity (TTM) -89.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7158092 | Price to Sales(TTM) - |
Enterprise Value -7158092 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.31 | Shares Outstanding 3943887 | Shares Floating 2568456 |
Shares Outstanding 3943887 | Shares Floating 2568456 | ||
Percent Insiders 7.73 | Percent Institutions 43.84 |
Upturn AI SWOT
Athira Pharma Inc
Company Overview
History and Background
Athira Pharma, Inc. was founded in 2011 and is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases. The company has evolved from preclinical research to clinical trials, focusing on small molecule therapies targeting the HGF/MET pathway.
Core Business Areas
- Neurological Therapeutics Development: Focuses on developing small molecule therapies to treat neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease.
Leadership and Structure
Athira Pharma's leadership team includes Mark Litton, Ph.D. (CEO), and other executives overseeing research, development, and operations. The organizational structure reflects a typical biotech company, with departments for R&D, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- Fosgonimeton: Fosgonimeton is Athira's lead investigational compound, targeting the HGF/MET pathway to treat Alzheimer's and Parkinson's disease. Currently in clinical trials. Market share is zero as it is not yet approved, but potential competitors include Biogen (BIIB), Eisai (ESALY), and Eli Lilly (LLY) who have approved or investigational Alzheimer's drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. The market for neurodegenerative disease treatments is large and growing, driven by an aging population. Regulatory hurdles and clinical trial risks are significant factors.
Positioning
Athira Pharma is a clinical-stage company focused on novel approaches to neurodegenerative diseases. Its competitive advantage lies in its specific therapeutic target (HGF/MET) and small molecule approach.
Total Addressable Market (TAM)
The global market for Alzheimer's disease therapeutics is expected to reach hundreds of billions of dollars. Athira Pharma is positioned to capture a share of this market if fosgonimeton is approved.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (HGF/MET)
- Small molecule approach (potential for oral administration)
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Clinical stage (high risk of failure)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on a single lead compound
- Past controversies related to data integrity
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory setbacks
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- BIIB
- ESALY
- LLY
- ABBV
Competitive Landscape
Athira Pharma competes with larger, more established pharmaceutical companies in the neurodegenerative disease market. Its advantage lies in its novel therapeutic target, but it faces significant challenges in terms of resources and clinical trial risk.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D spending and expansion of clinical trial programs.
Future Projections: Future growth depends on the successful development and commercialization of fosgonimeton. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing fosgonimeton through clinical trials, exploring new indications, and strengthening the leadership team.
Summary
Athira Pharma is a high-risk, high-reward clinical-stage biotech company focused on neurodegenerative diseases. While its novel therapeutic approach offers promise, it faces significant challenges related to clinical trial success, competition, and funding. The company's success hinges on the positive outcome of its clinical trials and ability to secure partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry databases
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice, and readers should conduct their own research before making investment decisions. Market share percentages are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Athira Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-09-18 | President, CEO & Director Dr. Mark J. Litton M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.athira.com |
Full time employees 26 | Website https://www.athira.com | ||
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.